PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.

Karuna Therapeutics, a US-based, neuropsychiatric-focused spinoff from pharmaceutical company PureTech Health, has gone public in an upsized $89.2m initial public offering on the Nasdaq Global Market. The offering consisted of approximately 5.58 million shares priced at $16.00 each, in the middle of the IPO’s range. Karuna increased the number of shares in the offering from…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.